Please login to the form below
ribociclib
This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
Latest news
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
-
Lilly boosted by survival data for key growth drug Verzenio
However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder.
-
Novartis raises 2019 guidance as new products gather speed
from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from
-
NICE says no to Novartis’ Kisqali combo in breast cancer
Draft guidance from the cost-effectiveness watchdog has concluded CDK 4/6 inhibitor Kisqali (ribociclib) plus fulvestrant should not be offered routinely on the NHS in England for patients with hormone ... More data may address the uncertainties in the
More from news
Approximately 4 fully matching, plus 32 partially matching documents found.
Latest appointments
-
Ipsen boosts specialty care and R&D leadership teams
East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
